E.i. Dupont De Nemours and Company

Dupont Pharmaceuticals Company

Other

The Dupont Merck Pharmaceutical Company

Bristol-myers Squibb Pharma Company

Munir A Hussain

Arnold J Repta

Douglas G Batt

Richard Eric Olson

Shaker Ahmed Mousa

Chu-Biao Xue

John Wityak

Gary Avonn Cain

Donald J Pinto

William Frank Degrado

Bruce J Aungst

Thais Motria Sielecki-Dzurdz

William John Pitts

Burton H Sage

Prabhakar Kondaji Jadhav

Philip G Green

Carl Randolph Bock

Lei-Shu Wu

Maher N Madhat

Raghunath Srinivas

The invention provides a method and device for administering an amine drug, such as &lsqb;S-(R,S)&rsqb;-2-&lsqb;4-&lsqb;&lsqb;(4-methyl)piperazin-1-yl&rsqb;carbonyl&rsqb;phenoxy&rsqb;-3,3-diethyl-N-&lsqb;1-(3,4-methylenedioxyphenyl)butyl&rsqb;-4-oxo-1-azetidinecarboxamide), in a sustained release dosage form. The invention includes a pharmaceutical composition and dosage form containing a polyalkylamine polymer and an amine drug. The polyalkylamine polymer is a hydrogel that forms hydrated particles when exposed to an aqueous environment. When mixed with the amine drug in the core of a coated tablet, the polyalkylamine polymer controls the release of the amine drug into an aqueous environment of use. The hydrated particles of the polymer together with the amine drug are released from the tablet core through plural apertures in the surrounding coat.

Use of polyalkylamine polymers in controlled release devices

This invention relates to novel heterocycles which are useful as antagonists of the &agr;,&bgr;,integrin and related cell surface adhesive protein receptors, to pharmaceutical compositions containing such compounds, to iontophoretic delivery of such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of cell adhesion, the treatment of angiogenic disorders, inflammation, bone degradation, cancer metastasis, diabetic retinopathy, thrombosis, restenosis, macular degeneration, and other conditions mediated by cell adhesion and/or cell migration and/or angiogenesis.

Integrin inhibitor prodrugs

This invention relates to novel methods and devices for iontophoretically administering therapeutic doses of integrin receptor antagonists in a controlled manner through the skin. Such integrin receptor antagonists include but are not limited to antagonists of the IIb/IIIa and &agr;,&bgr;,integrins and related cell surface adhesive protein receptors. The present invention includes iontophoretic delivery devices comprising integrin inhibitors. Such methods and devices are useful, alone or in combination with other therapeutic agents, for the treatment of thromboembolic disorders, angiogenic disorders, inflammation, bone degradation, cancer metastasis, diabetic retinopathy, restenosis, macular degeneration, and other conditions mediated by cell adhesion and/or cell migration and/or angiogenesis.

Iontophoretic delivery of integrin inhibitors

This invention relates to novel isoxazolines and isoxazoles which are useful as antagonists of the platelet glycoprotein IIb/IIIa fibrinogen receptor complex or the vitronectin receptor, to pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of platelet aggregation, as thrombolytics, and/or for the treatment of thromboembolic disorders.

Isoxazoline and isoxazole fibrogen receptor antagonists

Packaging of disposable gloves with consumer tissue products in order: To provide first aid protection (disposable gloves) in every type of package of consumer tissue products, and To utilize the widely used consumer tissue products as a vehicle to deliver the disposable gloves to end user. A new package form for consumer tissue products and particularly facial tissue for containing infectious body fluids resulting from the said injuries comprising: a) Any form of consumer package tissue products, b) One or more protective disposable gloves, c) Said gloves package having dimensions allowing said package to be incorporated in any existing forms and shapes of consumer tissue products and particularly facial tissue.

Packaging of disposable gloves with consumer tissue products

This invention relates to novel methods and devices for iontophoretically administering therapeutic doses of cell adhesion receptor antagonists in a controlled manner through the skin. Such antagonist compounds include but are not limited to antagonists of the IIb/IIIa and .alpha..sub.v .beta..sub.3 integrins and related cell surface adhesive protein receptors. The present invention includes iontophoretic delivery devices comprising cell adhesion receptor antagonists. Such methods and devices are useful, alone or in combination with other therapeutic agents, for the treatment of thromboembolic disorders, angiogenic disorders, inflammation, bone degradation, cancer metastasis, diabetic retinopathy, restenosis, macular degeneration, and other conditions mediated by cell adhesion and/or cell migration and/or angiogenesis.

Iontophoretic delivery of cell adhesion inhibitors

Isoxazoline and isoxazole fibrinogen receptor antagonists

The present invention relates to a dry powder composition of hydroxyethyl starch suitable for reconstitution and comprising hydroxyethyl starch of a molecular weight of up to about 2,000,000, a degree of substitution of from about 0.4 to about 0.7, and containing less than about 0.5 parts by weight of ethylene glycol per 100 parts of the hydroxyethyl starch, the hydroxyethyl starch comprising from about 4% to about 40% by weight of the composition. The composition includes at least one soluble component in addition to the hydroxyethyl starch chosen from dextrose, lactose or mannitol.

Dry powder composition of hydroxyethyl starch suitable for reconstitution

There is disclosed intranasal pharmaceutical compositions of 3,3-disubstituted indolines useful for treating cognitive or neurological dysfunction in a mammal. Also disclosed is a method of treating cognitive neurological dysfunction in a mammal comprising administering intranasally to the mammal, the 3,3-disubstituted indolines of formula (I).

Intranasal administration of 3,3-disubstituted indolines

Substituted benzoate ester prodrugs of .beta.-estradiol and ethynyl estradiol are provided which have improved bioavailability and extended duration of action when administered orally.

Substituted benzoate ester prodrugs of estrogens

Aliphatic, aromatic, carbonate, carbamate, or sulfonate ester prodrugs of 3-hydroxymorphinans lack the bitter taste of the parent compounds and provide enhanced bioavailability of 3-hydroxymorphinans from buccal, nasal, and sublingual dosage forms.

Growing community of inventors

Wilmington, DE, United States of America

Munir A Hussain